- Company
has signed partnership with Sanmina Corp., a global contract electronics
manufacturer, that sets the foundation for the commercialization and
launch of products
- SOLY’s
Rapid Acoustic Pulse device, designed to use shockwaves to accelerate
tattoo removal, received institutional review board approval as a
non-significant risk device
- Higher
energy versions of acoustic pulse devices are in early stages of
development for potential treatment of cellulite and other indications
Soliton Inc. (NASDAQ: SOLY) has reached an agreement with
Sanmina, one of the world’s largest medical device manufacturers, to provide
the design and testing to advance Soliton’s Rapid Acoustic Pulse (“RAP”) device
for use in future clinical trials. The successful execution of this strategy is
expected to lay the foundation for a commercial launch of Soliton’s
products (http://ibn.fm/NLeYu).
RAP is a device that uses proprietary platform technology
licensed from the MD Anderson Cancer Center. The device is designed to use
rapid pulses of acoustic shockwaves together with existing lasers to accelerate
the removal of unwanted tattoos.
Soliton also announced that its RAP device received
institutional review board approval as a non-significant risk device. The
FDA-registered board has been designated to review and monitor biomedical
research involving human subjects. Subsequently, Soliton conducted several
human clinical trials to study the use of the RAP device to accelerate tattoo
fading and also initiated a proof-of-concept trial in humans for the reduction
of cellulite (http://ibn.fm/iAY14).
“Working with Sanmina in this commercialization phase not
only provides us with world-class quality and documentation, but we also
believe it will make for a smoother transition to manufacturing, which we expect
to begin here in the US later this year,” Soliton CEO Dr. Chris Capelli stated
in a news release.
Based in Houston, Texas, Soliton is a medical device company
with a proprietary platform technology licensed from the University of Texas on
behalf of MD Anderson.
Also in the early stages of development is a device that
uses higher energy versions of acoustic pulse devices for potential stand-alone
treatment of cellulite and other indications. Both products by Soliton are
investigational and not yet available for sale in the United States.
For more information, visit the company’s website at www.Soliton.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
